Skip to main content
Sinocelltech Group Limited logo

Sinocelltech Group Limited — Investor Relations & Filings

Ticker · 688520 ISIN · CNE100003ZL3 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 659 across all filing types
Latest filing 2025-04-25 Governance Information
Country CN China
Listing Shanghai Stock Exchange 688520

About Sinocelltech Group Limited

https://www.sinocelltech.com/

Sinocelltech Group Limited focuses on the research, development, and commercialization of innovative biologics, including monoclonal antibodies, recombinant proteins, and vaccine candidates. The company's product pipeline addresses therapeutic areas such as oncology, autoimmune disorders, hematology, and infectious diseases. Key offerings include recombinant human coagulation factor VIII for hemophilia A and a range of biosimilars. Sinocelltech leverages an integrated technology platform encompassing early-stage discovery through to large-scale industrial production. This infrastructure supports the development of high-quality biological medicines aimed at addressing unmet medical needs through advanced protein engineering and cell line development.

Recent filings

Filing Released Lang Actions
股东会议事规则
Governance Information Classification · 100% confidence The document is titled "股东会议事规则" which translates to "Shareholders Meeting Rules" for Beijing Shenzhou Cell Technology Group Co., Ltd. It details the rules and procedures for convening and conducting shareholders meetings, including the rights and responsibilities of shareholders, meeting notices, voting procedures, proposal submissions, meeting discipline, and execution of resolutions. It is a governance document outlining internal rules and procedures related to shareholder meetings rather than a report of financial results, announcements, or meeting minutes. There is no indication that this is a report of an actual meeting, voting results, or a presentation. It is a governance framework document. Therefore, the most appropriate classification is Governance Information (CGR).
2025-04-25 Chinese
神州细胞股东减持股份计划公告
Major Shareholding Notification Classification · 100% confidence The document is a detailed announcement regarding a shareholder's plan to reduce their holdings in the company shares. It includes specifics about the shareholders involved, the number and percentage of shares to be reduced, the method and timing of the reduction, and compliance with relevant securities laws and regulations. There is no financial data, earnings information, or management discussion of financial results. The document is not a report or presentation but a formal notification of a planned shareholding reduction by certain shareholders. This fits the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels.
2025-04-22 Chinese
神州细胞关于副总经理辞职的公告
Board/Management Information Classification · 100% confidence The document is a formal announcement from the company's board regarding the resignation of the Vice General Manager, Dr. Zhanghua Lan, due to retirement. It includes details about the resignation, the effective date, shareholding information, and assurances about the impact on company operations. There is no financial data, no mention of financial results, no regulatory filings or certifications, and no reference to any report publication. The content clearly relates to a change in senior management. Therefore, this document fits the category of Board/Management Information (MANG). The document length is short and focused solely on management change, confirming the classification.
2025-03-31 Chinese
神州细胞自愿披露关于控股子公司产品SCTT11获得药物临床试验批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure announcement by Beijing Shenzhou Cell Biotechnology Group Co., Ltd. regarding its controlling subsidiary receiving approval from the National Medical Products Administration for a clinical trial of a product SCTT11. The content focuses on the approval notice, product details, clinical trial risks, and investor caution. It is a regulatory announcement about a clinical trial approval, not a financial report, earnings release, or management discussion. The document length is short (1306 characters) and it is an announcement of an event rather than a detailed report. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2025-03-06 Chinese
神州细胞自愿披露关于控股子公司获得药品注册证书的公告
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure announcement by Beijing Shenzhou Cell Biotechnology Group Co., Ltd. regarding its controlling subsidiary obtaining drug registration certificates from the National Medical Products Administration. It details the approval of new indications for two drugs, clinical trial results, and the potential impact on the company. The document is an official announcement about regulatory approval and business impact, not a financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial data. The document length is 2453 characters, which is relatively short and consistent with an announcement. Therefore, it fits best as a Regulatory Filing (RNS), which is a general regulatory announcement category for filings that do not fit other specific categories.
2025-02-28 Chinese
神州细胞2024年度业绩快报公告
Earnings Release Classification · 95% confidence The document is titled as a "2024年度业绩快报公告" which translates to "2024 Annual Performance Express Report Announcement." It contains preliminary financial data for the year 2024, including revenue, profit, and other key financial metrics. The data is explicitly stated as preliminary and unaudited, with a disclaimer that the final audited data will be in the 2024 Annual Report. The document is relatively short (2069 characters) and serves as a quick earnings summary rather than a full comprehensive report. It does not contain full financial statements or detailed analysis typical of an Annual Report (10-K) or Interim Report (IR). It is also not a simple announcement of report publication but a brief financial performance update. This fits the definition of an Earnings Release (ER), which is an initial announcement of quarterly or periodical financial results with key highlights only. FY 2024
2025-02-24 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.